Drug Type Trispecific killer cell engager (TriKE) |
Synonyms- |
Target |
Action activators, inhibitors, agonists |
Mechanism CD16 activators(FcγRIII activators), CD33 inhibitors(Myeloid cell surface antigen CD33 inhibitors), IL-15 agonists(Interleukin-15 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia | Preclinical | United States | 05 Nov 2025 | |
| Acute Myeloid Leukemia | Preclinical | United States | 05 Nov 2025 | |
| Acute Myeloid Leukemia | Preclinical | United States | 05 Nov 2025 |






